Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2015 Oct 06

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

Giornale Italiano di Dermatologia e Venereologia 2015 Oct 06

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series

Tambone S. 1, Fargnoli M. C. 1, Capizzi R. 2, Peris K. 2

1 Department of Dermatology, University of L’Aquila, Italy; 2 Institute of Dermatology, Catholic University of Rome, Italy


PDF  


AIM: In clinical studies, imiquimod 3.75% was shown to detect and treat actinic keratosis (AK) lesions across an entire sun-exposed field such as the full face or balding scalp. The aim of this study was to evaluate imiquimod 3.75% in a real-life clinical setting.
METHODS: Ten AK patients applied imiquimod 3.75% to the full face or scalp once- daily in two 2-week treatment cycles separated by a two-week treatment-free interval and were followed-up eight weeks later. Seven patients rated imiquimod 3.75% versus prior treatments (cryotherapy, photodynamic therapy, diclofenac sodium 3%, imiquimod 5%, ingenol mebutate).
RESULTS: The median clinical lesion count at baseline was 12.5. This increased to a median Lmax (maximum lesion count during treatment) of 22.5 as imiquimod 3.75% unmasked previously invisible subclinical lesions. At final follow-up, the median lesion count was zero. Local skin reactions such as erythema, scabbing and erosion occurred during each treatment cycle and were easy to manage. All patients considered imiquimod 3.75% easier to apply than prior treatments and five reported fewer or similar side effects.
CONCLUSION: In this cohort, imiquimod 3.75% effectively cleared clinical and subclinical lesions across the entire affected field and was well tolerated.

inizio pagina

Publication History

Per citare questo articolo

Tambone S, Fargnoli MC, Capizzi R, Peris K. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series. G Ital Dermatol Venereol 2015 Oct 06. 

Corresponding author e-mail

ketty.peris@rm.unicatt.it